Ascentage Pharma Group International (FRA:36X)

Market Cap	1.91B +23.3%
Revenue (ttm)	46.43M -56.7%
Net Income	-137.78M
EPS	-0.42
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	363
Average Volume	71
Open	5.40
Previous Close	5.30
Day's Range	5.40 - 5.40
52-Week Range	0.85 - 10.00
Beta	n/a
RSI	40.97
Earnings Date	Mar 26, 2026

About FRA:36X

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 605
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 36X

Financial Performance

In 2024, FRA:36X's revenue was 980.65 million, an increase of 341.77% compared to the previous year's 221.98 million. Losses were -405.43 million, -56.20% less than in 2023.

Financial numbers in CNY